You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDesflurane
Accession NumberDB01189  (APRD00907)
TypeSmall Molecule
GroupsApproved
DescriptionDesflurane is a highly fluorinated methyl ethyl ether used for maintenance of general anaesthesia. Volatile agents such as desflurane may activate GABA channels and hyperpolarize cell membranes. In addition, they may inhibit certain calcium channels and therefore prevent release of neurotransmitters and inhibit glutamate channels. Volatile anesthetics easily partition into cellular membranes and could expand the volume of the cell membrane and subsequently distort channels necessary for sodium ion flux and the development of action potentials necessary for synaptic transmission. Desflurane preconditions human myocardium against ischemia through activation of mitochondrial K(ATP) channels, adenosine A1 receptor, and alpha and beta adrenoceptors.
Structure
Thumb
Synonyms
(+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
1,1,1,2-Tetrafluoro-2-(difluoromethoxy)ethane
Desflurane
Desflurano
Desfluranum
Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
Suprane
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Supraneliquid240 mL/240mLrespiratory (inhalation)Baxter Healthcare Corporation1992-09-18Not applicableUs
Supraneliquid100 %inhalationBaxter Corporation1996-12-23Not applicableCanada
Supraneliquid240 mL/240mLrespiratory (inhalation)Baxter Healthcare Corporation1992-09-18Not applicableUs
Supraneliquid240 mL/240mLrespiratory (inhalation)Baxter Healthcare Corporation1992-09-18Not applicableUs
Supraneliquid240 mL/240mLrespiratory (inhalation)General Injectables & Vaccines, Inc2012-04-25Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIICRS35BZ94Q
CAS number57041-67-5
WeightAverage: 168.0378
Monoisotopic: 168.000983916
Chemical FormulaC3H2F6O
InChI KeyInChIKey=DPYMFVXJLLWWEU-UHFFFAOYSA-N
InChI
InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H
IUPAC Name
2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
SMILES
FC(F)OC(F)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as halomethanes. These are organic compounds in which at least one of the four hydrogen atoms of methane (CH4) are replaced by halogen atoms.
KingdomOrganic compounds
Super ClassOrganohalogen compounds
ClassAlkyl halides
Sub ClassHalomethanes
Direct ParentHalomethanes
Alternative Parents
Substituents
  • Halomethane
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Alkyl fluoride
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use as an inhalation agent for induction and/or maintenance of anesthesia for inpatient and outpatient surgery in adults.
PharmacodynamicsDesflurane is a general inhalation anesthetic. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.
Mechanism of actionDesflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Desflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Desflurane also binds to and agonizes the GABA receptor, the large conductance Ca2+ activated potassium channel, the glycine receptors, and antagonizes the glutamate receptors.
Related Articles
AbsorptionRapidly absorbed into the circulation via the lungs following inhalation.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Minimally biotransformed in the liver in humans (approximately 0.02% of the quantity absorbed).

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9941
Caco-2 permeable+0.626
P-glycoprotein substrateNon-substrate0.883
P-glycoprotein inhibitor INon-inhibitor0.9415
P-glycoprotein inhibitor IINon-inhibitor0.9027
Renal organic cation transporterNon-inhibitor0.9311
CYP450 2C9 substrateNon-substrate0.8676
CYP450 2D6 substrateNon-substrate0.919
CYP450 3A4 substrateNon-substrate0.7556
CYP450 1A2 substrateNon-inhibitor0.6194
CYP450 2C9 inhibitorNon-inhibitor0.836
CYP450 2D6 inhibitorNon-inhibitor0.9466
CYP450 2C19 inhibitorNon-inhibitor0.707
CYP450 3A4 inhibitorNon-inhibitor0.9604
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8921
Ames testNon AMES toxic0.9042
CarcinogenicityCarcinogens 0.7045
BiodegradationNot ready biodegradable0.9566
Rat acute toxicity1.2690 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9724
hERG inhibition (predictor II)Non-inhibitor0.909
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Liquidinhalation100 %
Liquidrespiratory (inhalation)240 mL/240mL
Prices
Unit descriptionCostUnit
Suprane inhalation liquid0.76USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5617906 No1994-10-082014-10-08Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
boiling point23.5 °CNot Available
water solubilityNegligibleNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.54 mg/mLALOGPS
logP2.19ALOGPS
logP2.4ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)18.87ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.23 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity18.12 m3·mol-1ChemAxon
Polarizability7.89 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Leonid A. Rozov, Chialang Huang, Gerald G. Vernice, “Synthesis of desflurane.” U.S. Patent US5205914, issued June, 1991.

US5205914
General ReferencesNot Available
External Links
ATC CodesN01AB07
AHFS Codes
  • 28:04.00
PDB EntriesNot Available
FDA labelDownload (174 KB)
MSDSDownload (51.1 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Desflurane is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Desflurane is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Desflurane is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Desflurane is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Desflurane.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Desflurane is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desflurane.
AmiodaroneDesflurane may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Desflurane is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Desflurane is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Desflurane is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Desflurane is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Desflurane is combined with Amperozide.
AnagrelideDesflurane may increase the QTc-prolonging activities of Anagrelide.
AripiprazoleThe risk or severity of adverse effects can be increased when Desflurane is combined with Aripiprazole.
Arsenic trioxideDesflurane may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherDesflurane may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Desflurane is combined with Asenapine.
Atracurium besylateDesflurane may increase the neuromuscular blocking activities of Atracurium besylate.
AzaperoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Azaperone.
AzelastineDesflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desflurane.
AzithromycinDesflurane may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Desflurane is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Desflurane is combined with Barbital.
BedaquilineDesflurane may increase the QTc-prolonging activities of Bedaquiline.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Desflurane.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Desflurane is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Desflurane is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.
BrimonidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Desflurane is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desflurane.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Desflurane.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Desflurane.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desflurane.
ButacaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Desflurane is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Desflurane is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Desflurane is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desflurane.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desflurane.
CarbinoxamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Desflurane is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Desflurane is combined with Carisoprodol.
CeritinibDesflurane may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Desflurane is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Desflurane is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desflurane.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Desflurane.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desflurane.
ChloroquineDesflurane may increase the QTc-prolonging activities of Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorphenamine.
ChlorpromazineDesflurane may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desflurane.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desflurane.
CiprofloxacinDesflurane may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideDesflurane may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Desflurane is combined with Citalopram.
ClarithromycinDesflurane may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Desflurane is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Desflurane is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Desflurane is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Desflurane is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desflurane.
ClozapineDesflurane may increase the QTc-prolonging activities of Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Desflurane.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Desflurane.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Desflurane.
CrizotinibDesflurane may increase the QTc-prolonging activities of Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Desflurane is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desflurane.
CyproheptadineThe risk or severity of adverse effects can be increased when Desflurane is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desflurane.
DapoxetineThe risk or severity of adverse effects can be increased when Desflurane is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Desflurane is combined with deramciclane.
DesipramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desflurane is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desflurane.
DextromoramideThe risk or severity of adverse effects can be increased when Desflurane is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desflurane.
DezocineThe risk or severity of adverse effects can be increased when Desflurane is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Desflurane.
DifenoxinThe risk or severity of adverse effects can be increased when Desflurane is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Desflurane is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desflurane.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desflurane.
DisopyramideDesflurane may increase the QTc-prolonging activities of Disopyramide.
DofetilideDesflurane may increase the QTc-prolonging activities of Dofetilide.
DolasetronDesflurane may increase the QTc-prolonging activities of Dolasetron.
DomperidoneDesflurane may increase the QTc-prolonging activities of Domperidone.
DopamineDesflurane may increase the arrhythmogenic activities of Dopamine.
DoramectinThe risk or severity of adverse effects can be increased when Desflurane is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Desflurane is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.
DoxylamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Desflurane is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Desflurane.
DronedaroneDesflurane may increase the QTc-prolonging activities of Dronedarone.
DroperidolDesflurane may increase the QTc-prolonging activities of Droperidol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Desflurane.
DrotebanolThe risk or severity of adverse effects can be increased when Desflurane is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desflurane.
EcgonineThe risk or severity of adverse effects can be increased when Desflurane is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Desflurane is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Desflurane is combined with Efavirenz.
EliglustatDesflurane may increase the QTc-prolonging activities of Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Desflurane.
EntacaponeThe risk or severity of adverse effects can be increased when Desflurane is combined with Entacapone.
EphedraEphedra may increase the arrhythmogenic activities of Desflurane.
EphedrineEphedrine may increase the arrhythmogenic activities of Desflurane.
EpinephrineDesflurane may increase the arrhythmogenic activities of Epinephrine.
ErythromycinDesflurane may increase the QTc-prolonging activities of Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Desflurane is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Desflurane is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desflurane.
EthanolDesflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Desflurane.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desflurane.
EthosuximideThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Desflurane is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Desflurane is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Desflurane.
EtoperidoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Desflurane is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Desflurane is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Desflurane is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desflurane.
FexofenadineThe risk or severity of adverse effects can be increased when Desflurane is combined with Fexofenadine.
FlecainideDesflurane may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Desflurane is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Desflurane is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Desflurane.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desflurane.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desflurane.
FluspirileneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluvoxamine.
FormoterolDesflurane may increase the arrhythmogenic activities of Formoterol.
FosphenytoinThe risk or severity of adverse effects can be increased when Desflurane is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Desflurane is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desflurane.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Desflurane is combined with gabapentin enacarbil.
Gadobenic acidDesflurane may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Desflurane is combined with Gamma Hydroxybutyric Acid.
GemifloxacinDesflurane may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Desflurane is combined with Glutethimide.
GoserelinDesflurane may increase the QTc-prolonging activities of Goserelin.
GranisetronDesflurane may increase the QTc-prolonging activities of Granisetron.
GuanfacineThe risk or severity of adverse effects can be increased when Desflurane is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Desflurane.
HaloperidolDesflurane may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Desflurane.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Desflurane.
HeroinThe risk or severity of adverse effects can be increased when Desflurane is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Desflurane is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Desflurane.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desflurane.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.
HydroxyzineThe risk or severity of adverse effects can be increased when Desflurane is combined with Hydroxyzine.
IbutilideDesflurane may increase the QTc-prolonging activities of Ibutilide.
IloperidoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Desflurane is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Desflurane.
IsoprenalineDesflurane may increase the arrhythmogenic activities of Isoprenaline.
KetamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Desflurane is combined with Lamotrigine.
LenvatinibDesflurane may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideDesflurane may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Desflurane is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Desflurane.
LevocabastineThe risk or severity of adverse effects can be increased when Desflurane is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Desflurane is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Desflurane is combined with Levodopa.
LevofloxacinDesflurane may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Desflurane is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Desflurane is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desflurane.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Desflurane.
LithiumThe risk or severity of adverse effects can be increased when Desflurane is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Desflurane is combined with Lofentanil.
LopinavirDesflurane may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Desflurane is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desflurane.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Desflurane.
Lu AA21004The risk or severity of adverse effects can be increased when Desflurane is combined with Lu AA21004.
LumefantrineDesflurane may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Desflurane.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Desflurane is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Desflurane is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Desflurane is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Desflurane.
MelperoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desflurane.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desflurane.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Desflurane.
MetaxaloneThe risk or severity of adverse effects can be increased when Desflurane is combined with Metaxalone.
MethadoneDesflurane may increase the QTc-prolonging activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Desflurane.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Desflurane is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Desflurane is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Desflurane.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Desflurane is combined with Methsuximide.
MethylphenidateMethylphenidate may increase the hypertensive activities of Desflurane.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desflurane.
MetyrosineDesflurane may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Desflurane.
MifepristoneMifepristone may increase the QTc-prolonging activities of Desflurane.
MilnacipranThe risk or severity of adverse effects can be increased when Desflurane is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desflurane.
MirtazapineDesflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desflurane.
MivacuriumDesflurane may increase the neuromuscular blocking activities of Mivacurium.
MolindoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Desflurane.
MoxifloxacinDesflurane may increase the QTc-prolonging activities of Moxifloxacin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Desflurane.
NabiloneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desflurane.
NilotinibDesflurane may increase the QTc-prolonging activities of Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitrous oxide.
NorepinephrineDesflurane may increase the arrhythmogenic activities of Norepinephrine.
NormethadoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Desflurane is combined with Nortriptyline.
OfloxacinDesflurane may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Desflurane is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Desflurane is combined with Olopatadine.
OndansetronDesflurane may increase the QTc-prolonging activities of Ondansetron.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Desflurane.
OpiumThe risk or severity of adverse effects can be increased when Desflurane is combined with Opium.
OrphenadrineDesflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Desflurane.
OsanetantThe risk or severity of adverse effects can be increased when Desflurane is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desflurane.
OxprenololThe risk or severity of adverse effects can be increased when Desflurane is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Desflurane.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desflurane.
OxymorphoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Paliperidone.
PanobinostatDesflurane may increase the QTc-prolonging activities of Panobinostat.
ParaldehydeDesflurane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Desflurane.
ParoxetineThe risk or severity of adverse effects can be increased when Desflurane is combined with Paroxetine.
PazopanibDesflurane may increase the QTc-prolonging activities of Pazopanib.
PentamidineDesflurane may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desflurane.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Desflurane.
PerampanelThe risk or severity of adverse effects can be increased when Desflurane is combined with Perampanel.
PerflutrenDesflurane may increase the QTc-prolonging activities of Perflutren.
PerospironeThe risk or severity of adverse effects can be increased when Desflurane is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Desflurane.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desflurane.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Desflurane.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Desflurane is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Desflurane is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Desflurane.
PipamperoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Desflurane is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Desflurane is combined with Pomalidomide.
PramipexoleDesflurane may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desflurane.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Desflurane.
PrimaquineDesflurane may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Primidone.
ProcainamideDesflurane may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Desflurane.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desflurane.
PromazineDesflurane may increase the QTc-prolonging activities of Promazine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Desflurane.
PromethazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Promethazine.
PropafenoneDesflurane may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Desflurane.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Desflurane.
PropoxycaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Desflurane is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Desflurane is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Desflurane is combined with Quetiapine.
QuinidineDesflurane may increase the QTc-prolonging activities of Quinidine.
QuinineDesflurane may increase the QTc-prolonging activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Desflurane is combined with Ramelteon.
RapacuroniumDesflurane may increase the neuromuscular blocking activities of Rapacuronium.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desflurane.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Desflurane.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Desflurane.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Desflurane.
RomifidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Romifidine.
RopiniroleDesflurane may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desflurane.
RotigotineDesflurane may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Desflurane.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Desflurane is combined with S-Ethylisothiourea.
SaquinavirDesflurane may increase the QTc-prolonging activities of Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desflurane.
SertindoleThe risk or severity of adverse effects can be increased when Desflurane is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Desflurane is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Desflurane is combined with Sodium oxybate.
SotalolDesflurane may increase the QTc-prolonging activities of Sotalol.
StiripentolThe risk or severity of adverse effects can be increased when Desflurane is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desflurane.
SulfisoxazoleDesflurane may increase the QTc-prolonging activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Desflurane.
SuvorexantThe risk or severity of adverse effects can be increased when Desflurane is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Desflurane is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Desflurane is combined with Tasimelteon.
TelavancinDesflurane may increase the QTc-prolonging activities of Telavancin.
TelithromycinDesflurane may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Desflurane.
TetrabenazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Desflurane is combined with Tetrodotoxin.
ThalidomideDesflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Desflurane.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desflurane.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Desflurane.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Desflurane.
ThiothixeneThe risk or severity of adverse effects can be increased when Desflurane is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Desflurane is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Desflurane is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Desflurane is combined with Topiramate.
ToremifeneDesflurane may increase the QTc-prolonging activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Desflurane.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desflurane.
TrazodoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Desflurane.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desflurane.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desflurane.
TrimipramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Desflurane.
VandetanibDesflurane may increase the QTc-prolonging activities of Vandetanib.
VemurafenibDesflurane may increase the QTc-prolonging activities of Vemurafenib.
VigabatrinThe risk or severity of adverse effects can be increased when Desflurane is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Desflurane is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desflurane.
ZiconotideThe risk or severity of adverse effects can be increased when Desflurane is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Desflurane.
ZolazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Desflurane.
ZonisamideThe risk or severity of adverse effects can be increased when Desflurane is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Desflurane is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Desflurane is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Desflurane is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Transmitter-gated ion channel activity
Specific Function:
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
Gene Name:
GLRA1
Uniprot ID:
P23415
Molecular Weight:
52623.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Grasshoff C, Antkowiak B: Effects of isoflurane and enflurane on GABAA and glycine receptors contribute equally to depressant actions on spinal ventral horn neurones in rats. Br J Anaesth. 2006 Nov;97(5):687-94. Epub 2006 Sep 13. [PubMed:16973644 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Pdz domain binding
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIA1
Uniprot ID:
P42261
Molecular Weight:
101505.245 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Dildy-Mayfield JE, Eger EI 2nd, Harris RA: Anesthetics produce subunit-selective actions on glutamate receptors. J Pharmacol Exp Ther. 1996 Mar;276(3):1058-65. [PubMed:8786535 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which ...
Gene Name:
KCNA1
Uniprot ID:
Q09470
Molecular Weight:
56465.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Matchett GA, Allard MW, Martin RD, Zhang JH: Neuroprotective effect of volatile anesthetic agents: molecular mechanisms. Neurol Res. 2009 Mar;31(2):128-34. doi: 10.1179/174313209X393546. [PubMed:19298752 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Signal transducer activity
Specific Function:
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium.
Gene Name:
ATP2C1
Uniprot ID:
P98194
Molecular Weight:
100576.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Transporter activity
Specific Function:
Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked toget...
Gene Name:
ATP5D
Uniprot ID:
P30049
Molecular Weight:
17489.755 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kosk-Kosicka D, Roszczynska G: Inhibition of plasma membrane Ca(2+)-ATPase activity by volatile anesthetics. Anesthesiology. 1993 Oct;79(4):774-80. [PubMed:8214757 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Nadh dehydrogenase (ubiquinone) activity
Specific Function:
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).
Gene Name:
MT-ND1
Uniprot ID:
P03886
Molecular Weight:
35660.055 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Sawas AH, Pentyala SN, Rebecchi MJ: Binding of volatile anesthetics to serum albumin: measurements of enthalpy and solvent contributions. Biochemistry. 2004 Oct 5;43(39):12675-85. [PubMed:15449957 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23